Antimicrobial Susceptibility Trends Among Gram-Negative Bacilli Causing Bloodstream Infections: Results from the China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2011–2020

References

• Cecconi M, Evans L, Levy M, et al. Sepsis and septic shock. Lancet. 2018;392:75–87. doi:10.1016/S0140-6736(18)30696-2
   PubMed Web of Science ®Google Scholar
• Qu J, Feng C, Li H, et al. Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection. Int J Antimicrob Agents. 2021;57:106284. doi:10.1016/j.ijantimicag.2021.106284
   Web of Science ®Google Scholar
• McNamara JF, Righi E, Wright H, et al. Long-term morbidity and mortality following bloodstream infection: a systematic literature review. J Infect. 2018;77:1–8. doi:10.1016/j.jinf.2018.03.005
   Web of Science ®Google Scholar
• Kern WV, Rieg S. Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect. 2020;26:151–157. doi:10.1016/j.cmi.2019.10.031
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Hsueh P-R, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother. 2019;63:e00355–19. doi:10.1128/AAC.00355-19
   PubMed Web of Science ®Google Scholar
• Al-Orphaly M, Hadi HA, Eltayeb FK, et al. Epidemiology of multidrug-resistant Pseudomonas aeruginosa in the Middle East and North Africa region. mSphere. 2021;6:e00202–21. doi:10.1128/mSphere.00202-21
   PubMed Web of Science ®Google Scholar
• Bassetti M, De Waele JJ, Eggimann P, et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med. 2015;41:776–795. doi:10.1007/s00134-015-3719-z
   PubMed Web of Science ®Google Scholar
• Akova M. Epidemiology of antimicrobial resistance in bloodstream infections. Virulence. 2016;7:252–266. doi:10.1080/21505594.2016.1159366
   PubMed Web of Science ®Google Scholar
• Yang S, Xu H, Sun J, et al. Shifting trends and age distribution of ESKAPEEc resistance in bloodstream infection, Southwest China, 2012–2017. Antimicrob Resist Infect Control. 2019;8:61. doi:10.1186/s13756-019-0499-1
   Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Karageorgopoulos DE, et al. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20:1170–1175. doi:10.3201/eid2007.121004
   PubMed Web of Science ®Google Scholar
• Stewardson AJ, Allignol A, Beyersmann J, et al. The health and economic burden of bloodstream infections caused by antimicrobial susceptible and non-susceptible Enterobacteriaceae and Staphylococcus aureus in European hospitals, 2010 and 2011: a multicentre retrospective cohort study. Euro Surveill. 2016;21:pii=30319. doi:10.2807/1560-7917.ES.2016.21.33.30319
   Google Scholar
• Liu X, Wang Y, Cui L, et al. A retrospective study on mcr-1 in clinical Escherichia coli and Klebsiella pneumoniae isolates in China from 2007 to 2016. J Antimicrob Chemother. 2018;73:1786–1790. doi:10.1093/jac/dky092
   PubMed Web of Science ®Google Scholar
• Liu XJ, Lyu Y, Li Y, et al. Trends in antimicrobial resistance against Enterobacteriaceae strains isolated from blood: a 10-year epidemiological study in mainland China (2004–2014). Chin Med J. 2017;130(17):2050–2055. doi:10.4103/0366-6999.213407.
   Web of Science ®Google Scholar
• Zhang F, Li Y, Lv Y, et al. Bacterial susceptibility in bloodstream infections: results from China Antimicrobial Resistance Surveillance Trial (CARST) program, 2015–2016. J Glob Antimicrob Resist. 2019;17:276–282. doi:10.1016/j.jgar.2018.12.016
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically Ninth Edition: Approved Standard M7-A9. CLSI, Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012.
   Google Scholar
• Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Thirty-First Informational Supplement M100-S31. CLSI, Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2021.
   Google Scholar
• Zhang Z, Chen M, Yu Y, et al. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012–2016 as part of the Tigecycline Evaluation and Surveillance Trial. Antimicrob Resist Infect Control. 2018;7:152. doi:10.1186/s13756-018-0441-y
   Web of Science ®Google Scholar
• Yungyuen T, Chatsuwan T, Plongla R, et al. Nationwide surveillance and molecular characterization of critically drug-resistant Gram-negative bacteria: results of the Research University Network Thailand study. Antimicrob Agents Chemother. 2021;65:e00675–21. doi:10.1128/AAC.00675-21
   Web of Science ®Google Scholar
• De Angelis G, Fiori B, Menchinelli G, et al. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007–2015). Eur J Clin Microbiol Infect Dis. 2018;37:1627–1636. doi:10.1007/s10096-018-3292-9
   Web of Science ®Google Scholar
• Xu A, Zheng B, Xu YC, et al. National epidemiology of carbapenem-resistant and extensively drug-resistant Gram-negative bacteria isolated from blood samples in China in 2013. Clin Microbiol Infect. 2016;22(Suppl 1):S1–8. doi:10.1016/j.cmi.2015.09.015
   PubMed Web of Science ®Google Scholar
• Hu F, Zhu D, Wang F, et al. Current status and trends of antibacterial resistance in China. Clin Infect Dis. 2018;67(suppl_2):S128–S134. doi:10.1093/cid/ciy657
   PubMed Web of Science ®Google Scholar
• Hu F, Guo Y, Yang Y, et al. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 2019;38(12):2275–2281. doi:10.1007/s10096-019-03673-1
   PubMed Web of Science ®Google Scholar
• Yu Y, Ji S, Chen Y, et al. Resistance of strains producing extended-spectrum beta-lactamases and genotype distribution in China. J Infect. 2007;54(1):53–57. doi:10.1016/j.jinf.2006.01.014
   PubMed Web of Science ®Google Scholar
• Xia S, Fan X, Huang Z, et al. Dominance of CTX-M-type extended-spectrum β-lactamase (ESBL)-producing Escherichia coli isolated from patients with community-onset and hospital-onset infection in China. PLoS One. 2014;9(7):e100707. doi:10.1371/journal.pone.0100707
   PubMed Web of Science ®Google Scholar
• Bush K, Bradford PA. Epidemiology of β-lactamase-producing pathogens. Clin Microbiol Rev. 2020;33(2):e00047–19. doi:10.1128/CMR.00047-19
   PubMed Web of Science ®Google Scholar
• Zhang R, Liu L, Zhou H, et al. Nationwide surveillance of clinical carbapenem-resistant Enterobacteriaceae (CRE) strains in China. EBioMedicine. 2017;19:98–106. doi:10.1016/j.ebiom.2017.04.032
   PubMed Web of Science ®Google Scholar
• Mojica MF, Rossi M-A, Vila AJ, et al. The urgent need for metallo-β-lactamase inhibitors: an unattended global threat.. Lancet Infect Dis. 2021;22(1):S1473-3099(20)30868–9. doi:10.1016/S1473-3099(20)30868-9
   Web of Science ®Google Scholar
• Yin D, Wu S, Yang Y, et al. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the in vitro activities of ceftazidime-avibactam and ceftolozane-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;63:e02431–18. doi:10.1128/AAC.02431-18
   PubMed Web of Science ®Google Scholar
• Yahav D, Giske CG, Grāmatniece A, et al. New β-lactam-β-lactamase inhibitor combinations. Clin Microbiol Rev. 2021;34:e00115–20. doi:10.1128/CMR.00021-21
   Web of Science ®Google Scholar
• Xue M, Wang K, Lu L, et al. Characterization of an New Delhi-Metallo-1-producing Enterobacter cloacae ST418 strain from a patient in Guangzhou, China. Microb Drug Resist. 2021;27:706–709. doi:10.1089/mdr.2020.0035
   Web of Science ®Google Scholar
• Zhao Y, Zhang J, Fu Y, et al. Molecular characterization of metallo-β-lactamase-producing carbapenem-resistant Enterobacter cloacae complex isolated in Heilongjiang Province of China. BMC Infect Dis. 2020;20:94. doi:10.1186/s12879-020-4768-7
   Web of Science ®Google Scholar
• Shortridge D, Gales AC, Streit JM, et al. Geographic and temporal patterns of antimicrobial resistance in Pseudomonas aeruginosa over 20 years from the SENTRY Antimicrobial Surveillance Program, 1997–2016. Open Forum Infect Dis. 2019;6(Suppl 1):S63–S68. doi:10.1093/ofid/ofy343
   PubMed Web of Science ®Google Scholar
• Horcajada JP, Montero M, Oliver A, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin Microbiol Rev. 2019;32:e00031–19. doi:10.1128/CMR.00031-19
   PubMed Web of Science ®Google Scholar
• De Oliveira DMP, Forde BM, Kidd TJ, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33:e00181–19. doi:10.1128/CMR.00181-19
   PubMed Web of Science ®Google Scholar
• Xie R, Zhang XD, Zhao Q, Peng B, Zheng J. Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerg Microbes Infect. 2018;7(1):31. doi:10.1038/s41426-018-0038-9
   PubMed Web of Science ®Google Scholar
• Cai Y, Chai D, Wang R, Liang B, Bai N. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother. 2012;67(7):1607–1615. doi:10.1093/jac/dks084
   PubMed Web of Science ®Google Scholar